NASDAQ · KYTX
Kyverna Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for KYTX: Nov 11, 2026
Kyverna Therapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.68. The reported EPS for the same quarter last year was $-0.85.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.68 | $-0.65 | $-0.70 | 4 |
| Dec 2026 | $-0.73 | $-0.68 | $-0.77 | 4 |
| Mar 2027 | $-0.78 | $-0.71 | $-0.84 | 3 |
| Jun 2027 | $-0.78 | $-0.70 | $-0.89 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · The Motley Fool · Zacks- BNK Invest · Oct 26, 4:44 PM EDTOversold Conditions For Kyverna Therapeutics (KYTX)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- RTTNews · Oct 21, 12:44 PM EDTKyverna's Miv-cel Shows 49% Walking Improvement At One Year; Stock Down(RTTNews) – Kyverna Therapeutics, Inc. (KYTX) announced one-year results from its registrational Phase 2 KYSA-8 trial, demonstrating sustained clinical benefits of miv-cel in patients with stiff person syndrome (SPS).
- RTTNews · Oct 21, 11:54 AM EDTKyverna's CAR T Therapy Shows Durable Results In Stiff Person Syndrome(RTTNews) – Kyverna Therapeutics (KYTX) reported one-year data from its Phase 2 KYSA-8 trial showing sustained benefits of miv-cel in stiff person syndrome.
- RTTNews · Sep 24, 7:46 AM EDTOne-Year Benefits Sustain Momentum For Kyverna's Autoimmune CAR-T Therapy; Stock Up(RTTNews) – Kyverna Therapeutics, Inc. (KYTX) reported positive one-year data for miv-cel, showing durable clinical responses and a favorable safety profile in patients with stiff person syndrome, while longer-term follow-up data in generalized myasthenia gravis also demonstrated
- RTTNews · Jul 13, 8:51 AM EDTCue Biopharma Appoints Dominic Borie As CMO(RTTNews) – Cue Biopharma, Inc. (CUE), on Monday, announced that it appointed Dominic Borie as Chief Medical Officer and Head of Research & Development, effective immediately.
- BNK Invest · Jul 10, 12:08 PM EDTFriday Sector Laggards: Biotechnology, DrugsIn trading on Friday, biotechnology shares were relative laggards, down on the day by about 4%. Helping drag down the group were shares of Kyverna Therapeutics, down about 14% and shares of Prime Medicine off about 13.6% on the day. Also lagging the market Friday are drugs sh
- The Motley Fool · Jun 8, 2:54 PM EDTKyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?Kyverna Therapeutics is a clinical-stage biopharmaceutical firm advancing cell therapies for autoimmune diseases.
- RTTNews · Jun 4, 2:22 AM EDTKyverna Reports Positive Phase 1 COMPARE Data For Miv-cel In Treating Rheumatoid Arthritis(RTTNews) – Kyverna Therapeutics Inc. (KYTX), a late-stage clinical biopharmaceutical company, on Wednesday reported updated Phase 1 data from the Phase 1/2 COMPARE trial for miv-cel in treating ACPA-positive, treatment-refractory rheumatoid arthritis. The results were presented
- RTTNews · May 18, 8:32 AM EDTKyverna Therapeutics Names Greg Martini CFO(RTTNews) – Kyverna Therapeutics, Inc. (KYTX), Monday announced the appointment of Greg Martini as Chief Financial Officer, effective May 18.
- RTTNews · Apr 24, 10:34 AM EDTWeekly Buzz: SNY, REGN Get FDA Nod; It's A No For ABBV, GRCE; LLY Acquires Kelonia(RTTNews) – This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multiple therapeutic areas, including Wilson's Disease, Ovarian cancer and stiff person syndrome.
- RTTNews · Apr 22, 3:08 AM EDTKyverna's Jumps On Positive Primary Results From KYSA-8 Trial Of KYV-101 In Stiff Person Syndrome(RTTNews) – Kyverna Therapeutics, Inc. (KYTX), a late-stage clinical biopharmaceutical company, announced positive primary analysis results from its registrational Phase 2 trial, KYSA-8, of miv-cel or KYV-101 in stiff person syndrome or SPS.
- Zacks · Dec 30, 7:58 AM ESTKyverna Therapeutics Stock Up 41% in a Month: Here's WhyKYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Kyverna Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.